- Drugs
- Wednesday, 18 Dec 2019
Medical Marijuana, Inc. Appoints New Chief Financial Officer
Medical Marijuana, Inc. (OTC: MJNA) (the "Company"), the first-ever publicly traded cannabis company in the United States that launched the world's first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that it has promoted its VP of Corporate Finance Brooke Beers to Chief Financial Officer of the Company.
"Brooke's contributions to the Company have been extraordinary," said Medical Marijuana, Inc. COO Blake Schroeder. "He's helped us overcome several financial obstacles that many cannabis companies face every day and he has helped us significantly improve our public reporting practices to increase transparency."
Beers was hired by Medical Marijuana, Inc. in 2017 and has since been leading the Company's accounting department, handling the Company's budget management, public financial reports, e-commerce offerings, and forecasting needs.
"Working with the Medical Marijuana, Inc. team has been an incredibly rewarding experience," said Beers. "Last December, the Brightfield Group reported that our Company represents 10 percent of the entire CBD market and I'm proud to be a part of that financial milestone and many more to come. It's encouraging to work with a large group of highly motivated professionals and claim our stake in the global CBD industry."
Related Industry Updates
Hikma receives FDA approval for its generic Vascepa®
May 22, 2020
Sialorrhea Treatment Market is expected to reach US$ 1,042.37 million by 2030
Dec 12, 2023
GeneQuantum Healthcare (GQ) receives IND clearance by the US FDA for ADC drug
Jun 11, 2020
Enteral Nutrition Market is expected to reach US$ 13,204.19 million by 2030
Oct 31, 2023
Synthetic Menthol Market Overview | COVID-19 Pandemic Impact, Competitive Landscape, Size, Value Demand, Regional Analysis and Forecast to 2027
May 06, 2021
Tocotrienol Market Estimated to Expand at a Robust CAGR over 2020-2027
Mar 15, 2021
CytoSorb® approved by the EU to remove rivaroxaban, a Factor Xa inhibitor
May 13, 2020